| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | PCRX Pacira Biosciences, Inc. | Williams Kristen76 | Chief Administrative Officer | Sell | 10,259 | $22.27 | $228,467.93 | -5.8% | - | - | |
| Jun 2, 2026 | NBIX Neurocrine Biosciences, Inc. | Cooke Julie59 | Chief Human Resources Officer | Sell | 36,937 | $156.22 | $5,770,235.26 | -18.0% | - | - | |
| Jun 1, 2026 | NBIX Neurocrine Biosciences, Inc. | Onyia Jude54 | Chief Scientific Officer | Sell | 11,000 | $160.25 | $1,762,710.40 | -29.9% | - | - | |
| Jun 1, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $547.91 | $5,205,104.61 | -2.4% | - | - | |
| Jun 1, 2026 | ALKS Alkermes Plc | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 9,000 | $41.67 | $375,043.50 | -10.4% | - | - | |
| Jun 1, 2026 | UTHR United Therapeutics Corporation | Edgemond James45 | CFO And Treasurer | Sell | 10,000 | $547.87 | $5,478,663.35 | -4.9% | - | - | |
| May 29, 2026 | ALKS Alkermes Plc | Parisi Samuel Joseph62 | VP, Finance (interim Pao) | Sell | 16,217 | $42.36 | $687,007.26 | -67.8% | - | - | |
| May 29, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $553.83 | $5,261,365.38 | -1.7% | - | - | |
| May 29, 2026 | PAHC Phibro Animal Health Corporation | Corcoran E Thomas61 | Director | Buy | 10,000 | $31.77 | $317,700.00 | +31.8% | - | - | |
| May 29, 2026 | NBIX Neurocrine Biosciences, Inc. | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 2,261 | $156.71 | $354,321.31 | -12.2% | - | - | |
| May 27, 2026 | NBIX Neurocrine Biosciences, Inc. | Onyia Jude54 | Chief Scientific Officer | Sell | 11,000 | $155.53 | $1,710,865.20 | -29.9% | - | - | |
| May 26, 2026 | NBIX Neurocrine Biosciences, Inc. | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 3,888 | $156.64 | $609,023.32 | -33.3% | - | - | |
| May 26, 2026 | LQDA Liquidia Corporation | Jeffs Roger67 | Chief Executive Officer | Sell | 75,000 | $61.01 | $4,575,675.00 | -2.3% | - | - | |
| May 21, 2026 | LQDA Liquidia Corporation | Singh Raman | Director | Sell | 29,494 | $60.13 | $1,773,435.88 | -43.2% | - | - | |
| May 19, 2026 | LQDA Liquidia Corporation | Caligan Partners LP58 | Director, 10% Owner, See Remarks | Sell | 5,300 | $59.98 | $317,894.00 | - | - | - | |
| May 19, 2026 | LQDA Liquidia Corporation | Caligan Partners LP58 | Director, 10% Owner, See Remarks | Buy | 5,300 | $59.98 | $317,894.00 | - | - | - | |
| May 18, 2026 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 7,950 | $23.64 | $187,915.74 | -2.9% | - | - | |
| May 15, 2026 | AQST Aquestive Therapeutics, Inc. | Barber Daniel72 | President And CEO | Sell | 8,257 | $4.29 | $35,413.45 | -1.2% | - | - | |
| May 13, 2026 | ZTS Zoetis Inc. | Damelio Frank A | Director | Buy | 6,650 | $75.39 | $501,343.50 | +44.9% | - | - | |
| May 13, 2026 | ZTS Zoetis Inc. | Bisaro Paul | Director | Buy | 2,000 | $75.88 | $151,750.00 | +7.7% | - | - | |
| May 12, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A58 | Chairperson &CEO | Sell | 9,500 | $578.38 | $5,494,562.96 | -1.5% | - | - | |
| May 12, 2026 | LQDA Liquidia Corporation | Jeffs Roger67 | Chief Executive Officer | Sell | 75,000 | $45.89 | $3,441,957.50 | -1.9% | - | - | |
| May 11, 2026 | ZTS Zoetis Inc. | McCallister Michael B | Director | Buy | 3,000 | $77.76 | $233,273.40 | +13.9% | - | - | |
| May 7, 2026 | PAHC Phibro Animal Health Corporation | Bendheim Jack49 | President And CEO | Sell | 18,608 | $54.61 | $1,016,227.66 | -4.1% | - | - | |
| May 6, 2026 | OGN Organon & Co. | Holzbaur Lynette | SVP And Corporate Controller | Buy | 26,448 | $13.35 | $353,080.40 | +100.2% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.